ADCTNYSEPharmaceutical PreparationsFiscal year ends December 31
ADC Therapeutics SA
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.44+0.04 (+2.86%)
Close on Oct 19, 2026
- Market cap
- $223.22M
- P/E (TTM)
- –
- Dividend yield
- –
ADC Therapeutics SA revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenues, net | $76.73M | $76.18M | $73.55M | $67.63M | $69.89M | $68.84M | $69.28M | $69.54M | $65.79M | $67.96M | $69.06M | – | 96.4% | +9.8% |
| Royalties | $2.86M | $3.00M | $2.81M | $2.58M | $2.36M | $1.98M | $1.56M | $1.18M | $958.00K | $664.00K | $498.00K | $351.00K | 3.6% | +21.2% |
| License revenues | $0 | $0 | $5.00M | $5.00M | $5.00M | $5.00M | $0 | – | – | – | – | – | 0.0% | -100.0% |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $76.73M | $76.18M | $73.55M | $67.63M | $69.89M | $68.84M | $69.28M | $69.54M | $65.79M | $67.96M | $69.06M | $72.22M | 96.4% | +9.8% |
| EMEA | $2.86M | $3.00M | $7.81M | $7.58M | $7.36M | $6.98M | $1.56M | $1.18M | $958.00K | $664.00K | $498.00K | $50.35M | 3.6% | -61.2% |
| Japan | – | – | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
From the segment and revenue-disaggregation notes of ADC Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.